Utah Medical Products, Inc. (NASDAQ: UTMD) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $205M. The Maz Rating grades it against the other companies in its sector.
Utah Medical Products, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $72.02, Utah Medical Products, Inc. trades at 21.4x trailing earnings, 5.8x sales and 1.8x book value, with an EV/EBITDA of 8.1. Over the last twelve months it generated about $35M of revenue and $10M of net income. It runs a gross margin of 57.7%, an operating margin of 29.9% and a net margin of 30.5%. It shows return on equity of 8.8%, return on invested capital of 6.9% and a free cash flow yield of 5.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 21.23. Over the past 52 weeks the share price ranged from $53.66 to $76.89, with a beta of 0.41.
Utah Medical Products, Inc. pays a dividend yielding 1.73%, with 37% of earnings paid out. Its Maz Dividend Score is 2.90 out of 5, ranked against the other dividend payers in its sector (Safety 2.83, Growth 1.50, Yield 3.37, Consistency 4.22).
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Utah Medical Products, Inc. (UTMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 36.8% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 36.8% / 33% · Receivables / Mkt Cap (36m) 1.71% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 36.8% / 33.33% · Receivables / Mkt Cap (24m) 1.71% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.2% / 33.33% · Receivables / Avg Assets (4Q) 2.94% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 66.3% / 33.33% · (Cash+Recv) / Total Assets 69.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Utah Medical Products, Inc. (UTMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Utah Medical Products, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Utah Medical Products, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.